Sprites
Mein FinanzNachrichtenJetzt AnmeldenPasswort vergessen?
Montag, 28.05.2012Börsentäglich über 11.000 News von 416 internationalen Medien
Erweiterte
Suche
Ad hoc-Mitteilungen

UCB SA

WKN: 852738  ISIN: BE0003739530  Ticker-Symbol: UNC 
Aktie:
Branche
Pharma
Aktienmarkt
EURONEXT-100
BEL-20
1-Jahres-Chart
UCB SA Chart 1 Jahr
1-Woche-Intraday-Chart
UCB SA 1-Woche-Intraday-Chart
RealtimeGeldBriefZeit
Taxe
38,357
38,745
27.05.

Aktuelle News zur UCB Aktie

  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache:
LeserMedien
23.05. 9
18.05. 44
ATLANTA, May 18, 2012 /PRNewswire/ -- UCB, Inc., a leading biopharmaceutical company dedicated to the research and development of treatments for severe central nervous system and immunological disorders...
Mehr lesen zu:
UCB Proudly Reinforces Long-Standing Commitment to Crohn's Disease Community at Digestive Disease Week 2012
18.05. 168
Das Analysehaus S&P Equity hat UCB von "Hold" auf "Sell" abgestuft und das Kursziel auf 33,00 Euro belassen. Der hohe Bewertungsaufschlag im Vergleich zu den Aktien der Wettbewerber sei nicht...
Mehr lesen zu:
S&P Equity senkt UCB auf 'Sell' - Ziel 33 Euro
16.05. 32
BioTrends Research Group, one of the world's leading research and advisory firms for specialized biopharmaceutical issues, finds that almost all pharmacotherapy-treated...
Mehr lesen zu:
Even as UCB's Keppra Captures the Largest Patient Share, Followed by GSK's Lamictal, Strong Company Support and Positive Efficacy Performance Drive Uptake of UCB's Vimpat in the Epilepsy Market, According to a Recent BioTrends Report
09.05. 19
30.04. 238
FOLGENDE WERTPAPIERE WERDEN AM 30.04.2012 EX DIVIDENDE GEHANDELT. THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 30.04.2012. INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT UZA XFRA CH0010567961...
Mehr lesen zu:
XFRA DIVIDEND INFORMATION - 30.04.2012 - 5
30.04. 277
FOLGENDE WERTPAPIERE WERDEN AM 30.04.2012 EX DIVIDENDE GEHANDELT. THE EX-DIVIDEND DAY OF THE FOLLOWING SHARES WILL BE 30.04.2012. INSTR EXCH ISIN INSTRUMENT NAME DIVIDEND AMOUNT BYG XETI FR0000120503...
Mehr lesen zu:
XETI DIVIDEND INFORMATION - 30.04.2012 - 2
27.04. 36
DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT: THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL UCB S.A. UNC BE0003739530 HZE/EOT
Mehr lesen zu:
XFRA UNC: AUSSETZUNG/SUSPENSION
27.04. 32
DIE FOLGENDE AKTIE IST AB SOFORT AUSGESETZT: THE FOLLOWING SHARE IS SUSPENDED WITH IMMEDIATE EFFECT: INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTIL UCB S.A. UNC BE0003739530 HZE/EOT
Mehr lesen zu:
XETI H UNC: AUSSETZUNG/SUSPENSION
24.04. 10
18.04. 51
ATLANTA, April 18, 2012 /PRNewswire/ --UCB, a leading biopharmaceutical company committed to the development of new epilepsy treatments and research, will sponsor multiple sets of...
Mehr lesen zu:
UCB Sponsors Data Presentations on Epilepsy and Vimpat® (lacosamide) C-V at the 64th Annual Meeting of the American Academy of Neurology
05.04. 91
Research and Markets (http://www.researchandmarkets.com/research/42209237/belgium_pharmaceut) has announced the addition of the "Belgium Pharmaceuticals and Healthcare...
Mehr lesen zu:
Research and Markets: Belgium Pharmaceuticals and Healthcare Report Q2 2012 - In 2012, Belgian Pharmaceutical Company UCB and Japanese Firm Otsuka Pharmaceutical Amended Their Collaboration to Focus on CNS Disorders
04.04. 2
04.04. 100
THOUSAND OAKS (dpa-AFX) - Amgen (AMGN) announced that, along with UCB SA (UCB), it initiated sclerostin antibody (CDP7851/AMG 785) Phase 3 clinical trial program for the treatment of postmenopausal...
Mehr lesen zu:
UCB,Amgen Begin Sclerostin Antibody Phase 3 Trial In Postmenopausal Osteoporosis
04.04. 96
BRUSSELS and THOUSAND OAKS, Calif., April 4, 2012 /PRNewswire/ --UCB (Euronext Brussels: UCB) and Amgen (NASDAQ:AMGN) announced today the start of their sclerostin antibody (CDP7851/AMG 785) Phase...
Mehr lesen zu:
UCB and Amgen Initiate Sclerostin Antibody Phase 3 Program in Patients With Postmenopausal Osteoporosis
02.04. 44
ATLANTA, April 2, 2012 /PRNewswire/ --On March 31, an estimated 5,000 people impacted by epilepsy rallied together on the National Mall in Washington, D.C. at the Epilepsy Foundation's National Walk...
Mehr lesen zu:
UCB Shines a Spotlight on the Trials and Triumphs of Living with Epilepsy with the "My Four Words" Project
28.03. 34
WASHINGTON, March 28, 2012 /PRNewswire/ --For the more than three million Americans who live with epilepsy, gaining seizure control is a top priority. Representatives from UCB and the Epilepsy Advocate...
Mehr lesen zu:
How Would You Describe Epilepsy if You Only Had Four Words? UCB and Epilepsy Advocate' Challenge National Walk for Epilepsy Attendees to Share Their Experience with Epilepsy in Four Words
23.03. 6
22.03. 24
20.03. 22
DUBLIN, CA -- (Marketwire) -- 03/20/12 -- Taleo Corporation (NASDAQ: TLEO), a global leader of SaaS-based Talent Management solutions, today announced that global biopharmaceutical leader UCB has...
Mehr lesen zu:
Taleo to Become UCB's Partner for Global Recruiting Project
Seite: 1 2 Weiter>>
33 Nachrichten in den letzten 6 Monaten